rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AQST
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Aquestive Therapeutics at Jefferies conference: anaphylm drives growth
      Nov 16Investing.comAQSTJEF
      Aquestive Therapeutics director buys $99,330 in shares
      Nov 12Investing.comAQST
      Aquestive Therapeutics: My Biotech Investment Framework Now Requires Me To Downgrade AQST To Sell
      Nov 11Seeking AlphaAQST
      Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
      Nov 9Yahoo FinanceAQST
      Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...

      Aquestive Therapeutics Inc (AQST) navigates quarterly revenue fluctuations while advancing Anifilm toward a March 2027 FDA decision and securing a $10 million upfront licensing deal for Libervant.

      Nov 6Yahoo FinanceAQST
      Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
      Nov 5Yahoo FinanceAQST
      Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceAQST
      Aquestive (AQST) Q3 2026 Earnings Call Transcript
      Nov 4The Globe and MailAQST
      What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
      Nov 4Yahoo FinanceAQST
      Earnings call transcript: Aquestive Therapeutics misses Q3 2026 estimates
      Nov 4Investing.comAQST
      Aquestive Therapeutics Q3 2026 Earnings Call Transcript
      Nov 4BenzingaAQST
      Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates

      Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.00% and -31.51%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 3Yahoo FinanceAQST
      Aquestive Therapeutics: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceAQST
      Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q3 2026 -- GF Value Sees 23% Downside
      Nov 3Yahoo FinanceAQST
      Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q3 2026 -- GF Value Sees 25% Downside
      Nov 2Yahoo FinanceAQST
      Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET

      WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report financial results for the third quarter ended September 30, 2026, and provide an update on recent developments in its business after market close on Tuesday, November 3, 2026. Management

      Oct 27Yahoo FinanceAQST
      Aquestive Therapeutics CEO sells $105,600 in shares
      Oct 16Investing.comAQST
      Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade (NASDAQ:AQST)

      Aquestive Therapeutics is upgraded to a Buy, anticipating Anaphylm approval and potential >$250m annual revenue by 2030. Click to read more on AQST.

      Oct 16Seeking AlphaAQST
      H.C. Wainwright reiterates Aquestive stock rating on FDA review
      Oct 16Investing.comAQST
      Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

      FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery techno

      Oct 15Yahoo FinanceAQST
      Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug - Aquestive Therapeutic

      Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.

      Oct 14BenzingaAQSTETON
      Aquestive rises on licensing deal with Eton (ETON:NASDAQ)
      Oct 14Seeking AlphaAQSTETON
      Eton licenses epilepsy drug LIBERVANT from Aquestive
      Oct 14Investing.comAQST
      Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST)

      Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. Learn why AQST stock is a hold.

      Sep 30Seeking AlphaAQST
      Aquestive Therapeutics Adds Veteran Executive to Board

      Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailAQST
      Aquestive appoints Rich Daly to board of directors
      Sep 29Investing.comAQST
      Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
      Sep 29Yahoo FinanceAQST
      Aquestive Therapeutics (AQST) Receives a Buy from H.C. Wainwright

      Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailAQST
      Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment
      Sep 17BenzingaAQST
      Aquestive resubmits drug application for anaphylaxis treatment
      Sep 17Investing.comAQST
      Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

      Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innova

      Sep 17Yahoo FinanceAQST
      Aquestive Therapeutics Resubmits Anaphylm NDA to FDA

      Aquestive Therapeutics (AQST) said Thursday that it resubmitted its New Drug Application to the FDA

      Sep 17Yahoo FinanceAQST
      Aquestive Therapeutics CEO Barber sells $120,487 in shares
      Sep 16Investing.comAQST
      Aquestive at H.C. Wainwright conference: anaphylm launch in focus
      Sep 14Investing.comAQST
      Cantor Fitzgerald reiterates Aquestive stock Overweight on Anaphylm profile
      Sep 10Investing.comAQST
      Aquestive at cantor healthcare conference: anaphylm launch nears
      Sep 9Investing.comAQST
      Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

      On August 11, Aquestive Therapeutics (NASDAQ:AQST) reported second-quarter 2026 results and said it remains on track to resubmit its Anaphylm epinephrine film to the FDA in the third quarter of 2026. That single sentence carries the whole story here. A company living and dying by one product candidate just cleared the studies standing between it […]

      Sep 8Yahoo FinanceAQST
      Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

      WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows: 2026 Wells Fargo Healthcare Conference: available to host investor meetings on Tuesday, September 8

      Sep 1Yahoo FinanceAQST

      This is the newest page. Registered accounts read further back.